全文获取类型
收费全文 | 36945篇 |
免费 | 1779篇 |
国内免费 | 306篇 |
专业分类
耳鼻咽喉 | 267篇 |
儿科学 | 659篇 |
妇产科学 | 416篇 |
基础医学 | 4905篇 |
口腔科学 | 1064篇 |
临床医学 | 2185篇 |
内科学 | 9294篇 |
皮肤病学 | 866篇 |
神经病学 | 2486篇 |
特种医学 | 1272篇 |
外科学 | 6577篇 |
综合类 | 147篇 |
一般理论 | 1篇 |
预防医学 | 1010篇 |
眼科学 | 637篇 |
药学 | 2139篇 |
中国医学 | 123篇 |
肿瘤学 | 4982篇 |
出版年
2023年 | 209篇 |
2022年 | 546篇 |
2021年 | 893篇 |
2020年 | 458篇 |
2019年 | 658篇 |
2018年 | 857篇 |
2017年 | 676篇 |
2016年 | 789篇 |
2015年 | 811篇 |
2014年 | 1094篇 |
2013年 | 1388篇 |
2012年 | 2270篇 |
2011年 | 2644篇 |
2010年 | 1498篇 |
2009年 | 1230篇 |
2008年 | 2261篇 |
2007年 | 2494篇 |
2006年 | 2341篇 |
2005年 | 2526篇 |
2004年 | 2429篇 |
2003年 | 2440篇 |
2002年 | 2446篇 |
2001年 | 410篇 |
2000年 | 347篇 |
1999年 | 478篇 |
1998年 | 593篇 |
1997年 | 472篇 |
1996年 | 441篇 |
1995年 | 376篇 |
1994年 | 331篇 |
1993年 | 303篇 |
1992年 | 234篇 |
1991年 | 218篇 |
1990年 | 215篇 |
1989年 | 211篇 |
1988年 | 187篇 |
1987年 | 134篇 |
1986年 | 125篇 |
1985年 | 110篇 |
1984年 | 124篇 |
1983年 | 97篇 |
1982年 | 79篇 |
1981年 | 93篇 |
1980年 | 89篇 |
1979年 | 70篇 |
1978年 | 48篇 |
1977年 | 36篇 |
1976年 | 25篇 |
1975年 | 29篇 |
1973年 | 30篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Koichiro Ina Toshio Hayashi Atsushi Araki Seinosuke Kawashima Hirohito Sone Hiroshi Watanabe Takashi Ohrui Koutaro Yokote Minoru Takemoto Kiyoshi Kubota Mitsuhiko Noda Hiroshi Noto Qun‐Fang Ding Jie Zhang Ze‐Yun Yu Byung‐Koo Yoon Hideki Nomura Masafumi Kuzuya Japan CDM Group 《Geriatrics & Gerontology International》2014,14(4):806-810
992.
993.
994.
995.
996.
Hisashi Hosoya Hideki Kitaura Takashi Hashimoto Mau Ito Masayuki Kinbara Toru Deguchi Toshiya Irokawa Noriko Ohisa Hiromasa Ogawa Teruko Takano-Yamamoto 《Sleep & breathing》2014,18(4):837-844
Purpose
Both obstructive sleep apnea syndrome (OSAS) and sleep bruxism (SB) are commonly related to arousal events. In this study, we examined the effect of SB on the sleep architecture and investigated the relationship between SB and sleep respiratory events in patients with OSAS.Methods
Patients with OSAS (n?=?67) in whom apnea/hypopnea occurred five or more times per hour were recruited to this study. Healthy volunteers (n?=?16) were recruited as controls. None of the healthy volunteers had any sleep disorders or medical disorders, nor had they taken any medication or alcohol. Data were collected by standard polysomnography during overnight sleep tests in a dark, quiet room.Results
The frequency of SB was higher in the OSAS than in the control group. The risk of SB was significantly higher in the OSAS than in the control group (odds ratio, 3.96; 95 % confidence interval, 1.03–15.20; P?0.05). Apnea/hypopnea and desaturation events occurred significantly more frequently in patients with than without SB. The frequency of the phasic type of SB correlated positively with that of obstructive apnea, micro-arousal, and oxygen desaturation. The frequency of SB events during micro-arousal events consequent on apnea/hypopnea events was significantly higher in the OSAS than in the control group.Conclusions
We found that patients with OSAS have a high risk of SB. In particular, this is the first report relating phasic-type SB to obstructive apnea events. This relationship suggests that improvement in OSAS might prevent exacerbations of SB. 相似文献997.
Hidetomo Nakamoto Xue‐Qing Yu Suhnggwon Kim Hideki Origasa Hongguang Zheng Jianghua Chen Kwon Wook Joo Suchai Sritippayawan Qinkai Chen Hung‐Chun Chen Yoshiharu Tsubakihara Hirofumi Tamai Sang Heon Song Indralingam Vaithilingam Kang Wook Lee Kuo‐Hsiung Shu Stanley Hok‐King Lo Masanao Isono Hajimu Kurumatani Kiyonobu Okada Hiroyuki Kanoh Takashi Kiriyama Shunsuke Yamada Toshiro Fujita 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》2020,24(1):42-55
TRK‐100STP, a sustained‐release preparation of the orally active prostacyclin analogue beraprost sodium, targets renal hypoxia. This study aimed to show the superiority of TRK‐100STP over placebos in patients with chronic kidney disease (with either primary glomerular disease or nephrosclerosis) to determine the recommended dose. CASSIOPEIR (Chronic Renal Failure Asian Study with Oral PGI2 Derivative for Evaluating Improvement of Renal Function) was a randomized, double‐blind, placebo‐controlled study conducted at 160 sites in seven Asia‐Pacific countries and regions. Eligible patients (n = 892) were randomized to TRK‐100STP 120, 240 μg, or placebo for a treatment period of up to 4 years. The primary efficacy endpoint was time to first occurrence of a renal composite: doubling of serum creatinine or occurrence of end‐stage renal disease. No significant differences were observed in composite endpoints between TRK‐100STP and placebo (P = 0.5674). Hazard ratios (95% CI) in the TRK‐100STP 120 and 240 μg vs. placebo groups were 0.98 (0.78, 1.22) and 0.91 (0.72, 1.14), respectively. The overall incidence of adverse events and adverse drug reactions was comparable between treatment arms. 相似文献
998.
999.